Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

BTAIQBTAIQ
3 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in BioXcel Therapeutics, Inc.

Yes. Citadel Advisors holds 149,220 shares of BTAIQ (BioXcel Therapeutics), worth $210,400, as of its Q2 2026 13F filing. It opened the position in Q2 2026.

Current Value

$210,400

Current Shares

149,220

Total Value Change

+$189,806

Total Shares Change

+137,842

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
New
149,220
-
$210,4000.0%$1.41
35
2025-Q3
Exited
0
-100.0%
$00.0%$2.56
0
2025-Q2
New
11,378
-
$20,5940.0%$1.81
29

Other major holders of BTAIQ: MILLENNIUM MANAGEMENT LLC, OAKTREE CAPITAL MANAGEMENT LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used